Polyethylene glycol (PEG) is one of the widely used functional polymer materials in modern biomedicine.
From PEGylation modification of proteins and peptide drugs to antibody–drug conjugates (ADCs), nucleic acid delivery, and nanomedicine design, PEG has become an important material tool in drug development due to its excellent hydrophilicity, biocompatibility, and well-established chemical modification chemistry.
PEGylation can improve the water solubility and stability of drug molecules, extend their circulation time in vivo, and regulate interactions between drugs and biological environments.
However, as drug development has gradually entered an era of molecular-level design, a long-standing question has attracted increasing attention:
Can the molecular structure of PEG really be described by only one average molecular weight?
From “Average Molecular Weight” to “Defined Structure”: PEG Is Undergoing a Transformation
Traditional PEG is typically prepared through polymerization processes. Therefore, the final product is not composed of a single molecular structure, but rather a mixture of PEG molecules with different chain lengths.
For example, a product labeled as PEG 5000 does not mean that every PEG molecule has a molecular weight of 5000 Da. Instead, it represents the average molecular weight of the entire sample, which actually contains PEG molecules within a certain molecular weight distribution range.
This polydispersity does not limit PEG’s large-scale applications. In many traditional applications, PEG is mainly required to provide functions such as hydrophilic protection and improved stability, and polydisperse PEG systems are sufficient to meet these needs.
However, when PEG becomes involved in more complex drug design, the situation begins to change.
In drug conjugation systems, PEG chain length can influence linker structures and spatial conformations. In nanodelivery systems, PEG chain length affects surface properties of materials. In functional material development, differences among PEG components may also influence the final performance of the materials.
At this stage, researchers are no longer concerned only with:
“Is PEG present?”
Instead, they are asking:
What exactly is the structure of PEG? Does every PEG molecule possess a consistent composition?
Monodisperse PEG has emerged in response to these demands.
Unlike traditional polydisperse PEG, monodisperse PEG possesses defined chain length, molecular weight, and terminal functional groups, transforming PEG from a material defined by average properties into a molecular module that can be designed and assembled.
Monodisperse PEG: Why Is It Called a “Molecular Standard Part”?
In industrial manufacturing, the value of standard parts lies in their well-defined specifications, which make the relationship between structure and performance easier to investigate and enable modular assembly.
Monodisperse PEG shares similar characteristics.
Traditional PEG is mainly regarded as a functional material, whereas monodisperse PEG further provides PEG with structural design capabilities.
Researchers can select PEG segments with different chain lengths, functional end groups, and connection strategies according to specific requirements, allowing PEG to serve as a defined molecular unit in drug and material design.
This structural consistency enables researchers to establish clearer relationships between:
PEG structure variation → Material property changes → Biological performance changes
This represents one of the key values of monodisperse PEG.
It is not simply about pursuing “higher purity PEG”; rather, it establishes a clearer connection between PEG chain length, molecular composition, and biological function.
Of course, achieving such structural consistency is challenging.
Compared with conventional polydisperse PEG obtained through polymerization, monodisperse PEG generally requires stepwise synthesis and refined purification processes to obtain PEG molecules with defined chain lengths, by analytical characterization to confirm their composition and purity.
For example, researchers have used chromatographic analysis to quantitatively evaluate monodisperse oligo(ethylene glycol) derivatives. PEG8, PEG12, and PEG16 derivatives achieved oligomer purities of 98.7%, 98.2%, and 97.0%, respectively, demonstrating the structural control capability of monodisperse PEG.
How Monodisperse PEG Influences Drug Design
PEGylation: PEG Chains Are No Longer Merely a “Protective Layer”
PEGylation is one of the important applications of PEG.
Through PEG modification, the stability and in vivo behavior of proteins, peptides, and small-molecule drugs can be improved.
In the past, PEG was often considered simply a “protective layer” that improved drug properties. However, studies involving monodisperse PEG have shown that PEG itself may influence drug performance through its molecular structure.
Taking polidocanol as an example, conventional polidocanol actually contains PEG components with different chain lengths. Researchers have further constructed monodisperse polidocanols with defined PEG chain lengths and compared them with conventional versions.
The results showed that monodisperse polidocanols exhibited higher biological activity and improved safety profiles compared with conventional polidocanol.
This study demonstrates that PEG chain structure is not merely an additional component, but may directly influence the final performance of a drug.
For PEGylated drugs, the ability to precisely define PEG structure represents the value of monodisperse PEG as a “molecular standard part.”
ADC: Improving Conjugation System Controllability Starting from Linker Structures
Antibody–drug conjugates (ADCs) have become an important area in cancer drug development in recent years.
A typical ADC consists of three key components: an antibody, a linker, and a payload. The antibody is responsible for recognizing target cells, the payload provides the pharmacological effect, and the linker determines how the two components are connected and when the drug is released.
Due to its excellent hydrophilicity and flexibility, PEG is frequently used in linker design for bioconjugation systems.
For ADCs, linker length, chemical structure, and stability can all influence the properties of the final conjugated product.
Modern ADC development increasingly emphasizes structural uniformity, including site-specific conjugation and control of the drug-to-antibody ratio (DAR). The fundamental goal is to reduce variations among different molecular species.
In this process, PEG linker modules with defined structures can provide a clearer design foundation.
This represents the value of structurally defined PEG modules: when the structure of the linker unit becomes clearer, researchers can more accurately analyze how different structural parameters influence the performance of conjugation systems.
Nanodelivery: PEG Chain Length Becomes a Material Design Parameter
PEG is also an important component in nanomedicine delivery systems.
In systems such as lipid nanoparticles (LNPs) and PLGA nanoparticles, PEG is commonly used to regulate particle surface properties, improve stability, and influence interactions between materials and biological environments.
Previously, PEG modification mainly focused on questions such as:
“Is PEG present?” and “How much PEG is incorporated?”
However, monodisperse PEG enables researchers to further investigate:
How do PEG segments with different chain lengths influence nanomaterial performance?
For example, in studies involving PEG-modified PLGA nanoparticles, researchers have used monodisperse PEGs with different chain lengths for comparison and quantitatively evaluated PEG conjugation efficiency.
This approach transforms PEG chain length from an ambiguous factor into an adjustable design parameter.
For nanodelivery systems, monodisperse PEG functions like a standardized interface, enabling more modular engineering of material surfaces.
Monodisperse PEG Is Driving PEG Toward an Era of Structural Design
The development of monodisperse PEG does not represent a simple replacement for traditional PEG.
Traditional PEG continues to play an important role in many biomedical applications due to its mature manufacturing processes and cost advantages.
However, in applications requiring more defined structures and deeper investigation of structure–function relationships, monodisperse PEG provides a new material option.
It enables PEG to evolve from a traditional functional component into a structured molecular tool.
Through the design of different chain lengths, terminal groups, and molecular topologies, monodisperse PEG can be further expanded into various fields, including drug conjugation, nucleic acid delivery, nanomaterial surface modification, and intelligent biomaterials.
From PEG Materials to Molecular Design Platforms
As biomedical research continues to advance toward more structured and functional molecular design, the demand for PEG materials has gradually expanded from simple functional modification toward more diverse molecular engineering.
Focusing on the needs of drug delivery and biomedical materials, SINOPEG continues to develop its PEG and PEG derivative product portfolio, covering different molecular weights, molecular architectures, terminal functional groups, and functionalized designs. These materials provide diverse molecular options for applications including protein and peptide modification, drug conjugation, nucleic acid delivery, and nanomaterial surface modification.
Currently, SINOPEG’s PEG product portfolio includes linear PEG, multi-arm PEG, and PEG derivatives with different functional end groups, providing corresponding material options for various application requirements.
From basic PEG materials to functional PEG derivatives, SINOPEG continues to advance PEG materials toward structural and functional development, providing a broader range of molecular tools for biomedical research and development.
When drug design enters the molecular era, PEG chain length can no longer be regarded merely as an average value.
It needs to become a defined structural parameter, a molecular unit that can be selected, assembled, and further developed.
This is the significance of monodisperse PEG as a “molecular standard part.”
References
Veronese FM, Pasut G. PEGylation, successful approach to drug delivery. Drug Discov Today. 2005 Nov 1;10(21):1451-8. doi: 10.1016/S1359-6446(05)03575-0. PMID: 16243265.
Kinbara, K. Monodisperse engineered PEGs for bio-related applications. Polym J 50, 689–697 (2018). https://doi.org/10.1038/s41428-018-0074-2
Adam M. Wawro, Takahiro Muraoka, Kazushi Kinbara; Chromatography-free synthesis of monodisperse oligo(ethylene glycol) mono-p-toluenesulfonates and quantitative analysis of oligomer purity. Polym. Chem. 2016; 7 (13): 2389–2394. https://doi.org/10.1039/c6py00127k
Tingjuan Wu, Kexin Chen, Shuangyan He, Xiaohe Liu, Xing Zheng, Zhong-Xing Jiang; Drug Development through Modification of Small Molecular Drugs with Monodisperse Poly(ethylene glycol)s. Org. Process Res. Dev. 21 August 2020; 24 (8): 1364–1372. https://doi.org/10.1021/acs.oprd.0c00273
Zeqiong Yu, Shaowei Bo, Huiyuan Wang, Yu Li, Zhigang Yang, Yongzhuo Huang, Zhong-Xing Jiang; Application of Monodisperse PEGs in Pharmaceutics: Monodisperse Polidocanols. Mol. Pharmaceutics 2 October 2017; 14 (10): 3473–3479. https://doi.org/10.1021/acs.molpharmaceut.7b00496
Tedeschini T, Campara B, Grigoletto A, Bellini M, Salvalaio M, Matsuno Y, Suzuki A, Yoshioka H, Pasut G. Polyethylene glycol-based linkers as hydrophilicity reservoir for antibody-drug conjugates. J Control Release. 2021 Sep 10;337:431-447. doi: 10.1016/j.jconrel.2021.07.041. Epub 2021 Jul 27. PMID: 34329685.
M. W. Giese, R. H. Woodman, G. T. Hermanson, and P. D. Davis, in Chemical Linkers in Antibody–Drug Conjugates (ADCs), ed. F. van Delft and J. M. Lambert, The Royal Society of Chemistry, 2021, ch. 9, pp. 286-376.
Tian X, Yuan Y. Impacts of polyethylene glycol (PEG) dispersity on protein adsorption, pharmacokinetics, and biodistribution of PEGylated gold nanoparticles. RSC Adv. 2024 Jul 1;14(29):20757-20764. doi: 10.1039/d4ra03153a. PMID: 38952930; PMCID: PMC11216039.
Basavci E, Mali A, Kalati M, Marques Marcilli R, Srinivas M. Monodisperse PEG engineering for quantifiable surface conjugation on PLGA nanoparticles. Nanoscale Adv. 2026 Jun 30;8(16):4500-4522. doi: 10.1039/d6na00116e. PMID: 42438481; PMCID: PMC13356874.
Junfei Zhu, Yan Xiao, Huaibin Zhang, Yu Li, Yaping Yuan, Zhigang Yang, Shizhen Chen, Xing Zheng, Xin Zhou, Zhong-Xing Jiang; Peptidic Monodisperse PEG “combs” with Fine-Tunable LCST and Multiple Imaging Modalities. Biomacromolecules 11 March 2019; 20 (3): 1281–1287. https://doi.org/10.1021/acs.biomac.8b01693
Mui BL, Tam YK, Jayaraman M, Ansell SM, Du X, Tam YY, Lin PJ, Chen S, Narayanannair JK, Rajeev KG, Manoharan M, Akinc A, Maier MA, Cullis P, Madden TD, Hope MJ. Influence of Polyethylene Glycol Lipid Desorption Rates on Pharmacokinetics and Pharmacodynamics of siRNA Lipid Nanoparticles. Mol Ther Nucleic Acids. 2013 Dec 17;2(12):e139. doi: 10.1038/mtna.2013.66. PMID: 24345865; PMCID: PMC3894582.
